Morgan Stanley Cuts Stake in Blueprint Medicines Corp (BPMC)
Morgan Stanley trimmed its position in Blueprint Medicines Corp (NASDAQ:BPMC) by 68.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 116,482 shares of the biotechnology company’s stock after selling 256,940 shares during the quarter. Morgan Stanley owned 0.27% of Blueprint Medicines worth $9,093,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in the stock. Candriam Luxembourg S.C.A. raised its holdings in shares of Blueprint Medicines by 2.3% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 45,000 shares of the biotechnology company’s stock valued at $3,513,000 after buying an additional 1,000 shares during the period. Jennison Associates LLC raised its holdings in shares of Blueprint Medicines by 0.8% during the 3rd quarter. Jennison Associates LLC now owns 222,540 shares of the biotechnology company’s stock valued at $17,371,000 after buying an additional 1,658 shares during the period. Public Employees Retirement Association of Colorado raised its holdings in shares of Blueprint Medicines by 56.7% during the 3rd quarter. Public Employees Retirement Association of Colorado now owns 4,718 shares of the biotechnology company’s stock valued at $368,000 after buying an additional 1,708 shares during the period. BlueMountain Capital Management LLC purchased a new stake in shares of Blueprint Medicines during the 3rd quarter valued at about $140,000. Finally, Fernwood Investment Management LLC purchased a new stake in shares of Blueprint Medicines during the 3rd quarter valued at about $210,000.
Shares of NASDAQ BPMC opened at $73.14 on Monday. Blueprint Medicines Corp has a fifty-two week low of $44.58 and a fifty-two week high of $109.00. The company has a quick ratio of 10.05, a current ratio of 10.05 and a debt-to-equity ratio of 0.03. The company has a market cap of $3.21 billion, a price-to-earnings ratio of -18.66 and a beta of 1.61.
WARNING: This piece of content was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://theolympiareport.com/2019/02/11/morgan-stanley-cuts-stake-in-blueprint-medicines-corp-bpmc.html.
Blueprint Medicines Profile
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Recommended Story: How to Invest in the Dividend Aristocrat Index
Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Corp (NASDAQ:BPMC).
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.